1. Collins FS, Koroshetz WJ, Volkow ND. JAMA, Helping to end addiction over the long-term: The research plan for the NIH HEAL initiative., 2018, 320, 129-130,
2. Krebs EE, Gravely A, Nugent S, Jensen AC, DeRonne B, Goldsmith ES, Kroenke K, Bair MJ, Noorbaloochi S. JAMA, Effect of opioid vs. nonopioid medications on pain-related function in patients with chronic back pain or hip or knee osteoarthritis pain: The SPACE randomized clinical trial., 2018, 319, 872-882,
3. Blum K, Oscar-Berman M, Jacobs W, McLaughlin T, Gold MS. J Addict Res Ther, Buprenorphine response as a function of neurogenetic polymorphic antecedents: Can dopamine genes affect clinical outcomes in Reward Deficiency Syndrome (RDS)?, 2014, 5, 1000185-,
4. Hill E, Han D, Dumouchel P, Dehak N, Quatieri T, Moehs C, Oscar-Berman M, Giordano J, Simpatico T, Barh D, Blum K. PLoS One, Long term Suboxone emotional reactivity as measured by automatic detection in speech., 2013, 8, e69043-,
5. Blum K, Modestino EJ, Badgaiyan RD, Baron D, Thanos PK, Elman I, Siwicki D, Febo M, Gold MS. EC Psychol Psychiatr, analysis of evidence for the combination of pro-dopamine regulator (KB220PAM) and naltrexone to prevent opioid use disorder relapse., 2018, 8, 564-579,